Browsing Tag
Cardiovascular drugs
2 posts
Is Merck building the next great cardiometabolic franchise? A closer look at WINREVAIR, enlicitide and Ohtuvayre
See how Merck is building a cardiometabolic growth engine with WINREVAIR, enlicitide and Ohtuvayre—and what it means for investors.
Top 5 PCSK9 inhibitor stocks to watch in 2025: From injectables to gene editing
Explore the top five PCSK9 inhibitor stocks—Amgen, Regeneron–Sanofi, Merck, Novartis, Verve—and what makes each a standout in cholesterol treatment in 2025.